Lv1
30 积分 2024-01-14 加入
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
23天前
已完结
Efficacy of Perioperative and Neoadjuvant Therapies in Gastric and Gastroesophageal Junction Adenocarcinoma: a Network Meta-Analysis
1个月前
已完结
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis
1个月前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
2个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
4个月前
已完结
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
4个月前
已完结
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
4个月前
已完结
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
8个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
10个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
1年前
已完结
皖公网安备34019202002308
